Uproar grows over drug's price
The $56,000 annual price for Biogen Inc.'s recently approved Alzheimer's disease therapy is drawing increasing criticism ahead of a decision by the U.S. government on reimbursement…
The $56,000 annual price for Biogen Inc.'s recently approved Alzheimer's disease therapy is drawing increasing criticism ahead of a decision by the U.S. government on reimbursement…